NASDAQ:PBYI Puma Biotechnology (PBYI) Stock Price, News & Analysis $9.06 -0.18 (-1.95%) As of 08/28/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Puma Biotechnology Stock (NASDAQ:PBYI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Puma Biotechnology alerts:Sign Up Key Stats Today's Range$9.02▼$9.2650-Day Range$7.66▼$9.4952-Week Range$4.30▼$9.51Volume235,035 shsAverage Volume326,210 shsMarket Capitalization$467.68 millionP/E Ratio17.42Dividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Puma Biotechnology, Inc. is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs. The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer. Nerlynx has since been explored in additional settings, including metastatic disease, reflecting Puma’s commitment to expanding therapeutic options for patients. Beyond its approved product, Puma Biotechnology maintains a clinical‐stage pipeline that includes additional oncology candidates and combination regimens under evaluation in multiple cancer indications. Through ongoing trials, the company aims to build on Nerlynx’s platform and bring new treatment options to patients facing aggressive tumors. Since completing its initial public offering on Nasdaq under the ticker PBYI in 2013, Puma has established commercial operations in the United States and forged partnerships to support product launches and regulatory filings in Europe and other global markets. Under the leadership of Founder and President/CEO Alan H. Auerbach, the company continues to leverage strategic collaborations and scientific expertise to drive its growth and development efforts.AI Generated. May Contain Errors. Read More Puma Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScorePBYI MarketRank™: Puma Biotechnology scored higher than 24% of companies evaluated by MarketBeat, and ranked 821st out of 919 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingPuma Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.Downside RiskPuma Biotechnology has a consensus price target of $6.00, representing about 33.8% downside from its current price of $9.06.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about Puma Biotechnology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-41.94% Earnings GrowthEarnings for Puma Biotechnology are expected to decrease by -41.94% in the coming year, from $0.31 to $0.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is 17.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.14.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is 17.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.16.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 3.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Puma Biotechnology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.38% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 11.39, which indicates bearish sentiment.Change versus previous monthShort interest in Puma Biotechnology has recently increased by 1.00%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment1.63 News SentimentPuma Biotechnology has a news sentiment score of 1.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Puma Biotechnology this week, compared to 2 articles on an average week. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,006,711.00 in company stock.Percentage Held by Insiders22.20% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Puma Biotechnology's insider trading history. Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBYI Stock News HeadlinesPuma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | seekingalpha.comPuma Biotechnology Reports Second Quarter 2026 Financial ResultsAugust 6, 2026 | businesswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial ResultsJuly 23, 2026 | finance.yahoo.comPuma Biotechnology Shareholders Back Governance, Reject Warrant ExtensionJune 16, 2026 | tipranks.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 3, 2026 | businesswire.comPuma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft EarningsMay 14, 2026 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00May 11, 2026 | finance.yahoo.comSee More Headlines PBYI Stock Analysis - Frequently Asked Questions How have PBYI shares performed this year? Puma Biotechnology's stock was trading at $5.95 on January 1st, 2026. Since then, PBYI stock has increased by 52.3% and is now trading at $9.06. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.15. The biopharmaceutical company earned $56.50 million during the quarter, compared to analysts' expectations of $53 million. Puma Biotechnology had a trailing twelve-month return on equity of 20.76% and a net margin of 11.50%. Read the conference call transcript. Who are Puma Biotechnology's major shareholders? Puma Biotechnology's top institutional shareholders include BlackRock Inc. (7.47%), Connor Clark & Lunn Investment Management Ltd. (1.25%), Globeflex Capital L P (0.74%) and Bank of New York Mellon Corp (0.71%). Insiders that own company stock include Alan H Auerbach, Douglas M Hunt, Maximo F Nougues, Brian M Stuglik, Jeffrey Jerome Ludwig, Alvin F Wong, Allison Dorval, Troy Edward Wilson, Jay M Moyes, Michael Patrick Miller, Alessandra Cesano and Adrian Senderowicz. View institutional ownership trends. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA). Company Calendar Last Earnings8/06/2026Today8/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (20m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 PBYI's financial health is in the Green zone, according to TradeSmith. PBYI has been in this zone for over 20 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PBYI CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees200Year Founded2010Price Target and Rating Average Price Target for Puma Biotechnology$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside-33.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.52 Trailing P/E Ratio17.42 Forward P/E Ratio29.23 P/E GrowthN/ANet Income$31.11 million Net Margins11.50% Pretax Margin13.48% Return on Equity20.76% Return on Assets13.22% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.64 Sales & Book Value Annual Sales$228.40 million Price / Sales2.05 Cash Flow$0.83 per share Price / Cash Flow10.86 Book Value$2.68 per share Price / Book3.38Miscellaneous Outstanding Shares51,620,000Free Float40,160,000Market Cap$467.68 million OptionableOptionable Beta1.22 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:PBYI) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredLeading AI Insider Issues Urgent Market WarningA leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBuy this stock todayMost tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...Chaikin Analytics | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
